Published in:
01-06-2020 | Fertility | Commentary
Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?
Authors:
Leena Nahata, Teresa K. Woodruff, Gwendolyn P. Quinn, Lillian R. Meacham, Diane Chen, Leslie C. Appiah, Courtney Finlayson, Kyle E. Orwig, Monica M. Laronda, Erin E. Rowell, Antoinette Anazodo, Olivia Frias, Julie Sroga Rios, Stacy Whiteside, Veronica Gomez-Lobo, Maggie Dwiggins, Krista J. Childress, Holly R. Hoefgen, Jennifer M. Levine, Yasmin Jayasinghe, Molly Moravek
Published in:
Journal of Assisted Reproduction and Genetics
|
Issue 6/2020
Login to get access
Excerpt
With steadily improving survival rates for childhood cancer and other pediatric medical conditions, it has become increasingly important to minimize anticipated adverse effects of therapies and optimize long-term quality of life [
1]. Reproductive dysfunction, including infertility, is a late effect of some therapies and infertility distress is often linked to psychosocial distress among female cancer survivors [
2,
3]. For these reasons, it is critical to offer options to protect and preserve fertility prior to initiating gonadotoxic therapies [
1]. …